Neoadjuvant Chemotherapy Induced Impairment of Natural Immunity in Breast Cancer Patients. Beitsch et al - American Assoc. Of Cancer Research. 1992.
Vivamus molestie gravida turpis
Natural Immunity in Breast Cancer Patients During Neoadjuvant Chemotherapy and after surgery. Beitsch et al - Surg Onc. 1994 Aug.
Chemosensitivity and endocrine sensitivity predicted by MammaPrint and BluePrint in clinical luminal patients in the prospective NBRST study. Gittleman et al - Presentation SABCS. 2015.
Pertuzumab overcomes chemotherapy/trastuzumab resistance in ER+/HER2+ tumors classified as Luminal functional subtype by 80-gene BluePrint assay in prospective neoadjuvant breast registry symphony trial. Beitsch Gittleman. Presentation SABCS. 2015.
1/3 of HER2 positive patients have 80-gene luminal subtype resistant to chemo-trastuzumab but sensitive to chemo-trastuzumab-pertuzumab: critical implications for adjuvant setting from NBRST phase 4 study. Beitsch- Presentation SABCS 2015.
Three distinct HER2 subtypes identified by BluePrint 80-gene functional subtyping predict treatment-specific response in the prospective neo-adjuvant NBRST registry. Gittleman and Whitworth et al - Presentation SABCS. 2015.